Litman Gregory Funds Trust Polen Capital China Growth ETF (ARCA: PCCE)

Últimas noticias sobre Litman Gregory Funds Trust Polen Capital China Growth ETF (ARCA:PCCE)

Communication Services

Consumer Cyclical

Financial Services

Other

Industrials

Real Estate

Basic Materials

Healthcare

Technology

Consumer Defensive

Utilities

PCCE aims for long-term capital growth through investment in an actively managed portfolio, primarily invests in common stock of companies that have either the predominant part of their assets in, their revenues derived from, or substantial business in, the Peoples Republic of China (PRC) and/ or Hong Kong. Advisor believe that consistent earnings growth is the primary driver of intrinsic value and long-term stock appreciation. Seek to invest in companies with a durable earnings profile driven by a sustainable competitive advantage, financial strength, sound ESG practices, proven management teams, and powerful products/ services.

Tencent Holdings Ltd

Ctrip.com International, Ltd., Adr

Meituan ADR

Trip.com Group Ltd., Convertible Usd

Netease

Xiaomi Corporation

Polen Capital China Growth ETF

Litman Gregory Funds Trust Polen Capital China Growth ETF

WIIM

AVAV

AeroVironment shares are trading lower after the company announced a proposed $750 million common stock offering and $600 million in convertible senior notes due 2030 to repay debt and expand manufacturing.

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

WYNN

Shares of casino stocks are trading lower after Macau June casino revenue reportedly rose.

JP Morgan analyst Joseph Greff upgrades Melco Resorts and Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLCO#NASDAQ">MLCO</a>) from Neutral to Overweight and raises the price target from $7.2 to $9.5.

News

Upgrades

Price Target

Analyst Ratings

JP Morgan Upgrades Melco Resorts and Enter to Overweight, Raises Price Target to $9.5

HC Wainwright &amp; Co. analyst Yi Chen maintains Lexaria Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>) with a Buy and lowers the price target from $7 to $5.

LEXX

HC Wainwright & Co. Maintains Buy on Lexaria Bioscience, Lowers Price Target to $5

TSLA

Tesla shares are trading lower amid disagreements between CEO Elon Musk and President Donald Trump. Additionally, Tesla registrations in Sweden and Denmark reportedly fell during June.

Needham analyst Charles Shi maintains Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) with a Buy and raises the price target from $225 to $270.

Needham Maintains Buy on Taiwan Semiconductor, Raises Price Target to $270

Accenture Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) announced on Tuesday that <a href="https://www.benzinga.com/pressreleases/25/07/b46188712/accenture-acquires-systema-to-drive-manufacturing-automation-for-semiconductor-clients">it has acquired</a> SYSTEMA GmbH, a Dresden-based software and consulting firm that specializes in automation solutions for the semiconductor and high-tech sectors.
The deal strengthens Accenture&#8217;s digital manufacturing capabilities; the financial terms were not disclosed. Headquartered in Dresden, SYSTEMA brings expertise in bridging legacy systems with modern automation technologies.
The acquisition aligns with Europe&#8217;s efforts to boost domestic semiconductor production, a priority amid growing global demand. SYSTEMA&#8217;s proficiency in connecting legacy systems with modern technologies will enhance Accenture&#8217;s ability to modernize industrial operations across the region.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/46166236/palantir-accenture-partner-to-infuse-ai-into-federal-agency-workflows" target="_blank" rel="noreferrer noopener">Palantir, Accenture Partner To Infuse AI Into Federal Agency Workflows</a>
Christina Raab, who leads Accenture&#8217;s operations across Austria, Switzerland, and Germany, emphasized the strategic value of the deal. &#8220;The semiconductor industry underpins much of today&#8217;s technology, and SYSTEMA&#8217;s specialized knowledge enhances our ability to support this complex sector,&#8221; she said.
Sarat Maitin, who heads Accenture&#8217;s digital engineering and manufacturing practice in the region, noted that the acquisition expands Accenture&#8217;s capacity to cover the full manufacturing value chain. &#8220;We aim to be a long-term strategic partner helping European clients remain competitive,&#8221; he said.
SYSTEMA is well-versed in SAP-based manufacturing execution systems and Critical Manufacturing solutions. Beyond semiconductors, the company serves industries such as aerospace, automotive, medical devices, and chemicals.
More than 240 SYSTEMA employees will join Accenture&#8217;s Industry X division, which focuses on digital manufacturing. As of May 31, 2025, Accenture held <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/46024923/accenture-new-bookings-fall-in-q3-but-it-raises-profit-outlook" rel="noreferrer noopener">$9.64 billion</a> in cash and equivalents.
Related ETFs: iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>), Global X Robotics &amp; Artificial Intelligence ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOTZ#NASDAQ">BOTZ</a>).
Price Action: ACN shares closed 1.16% higher at $298.89 on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46188671/nvidia-microsoft-on-track-to-achieve-4-trillion-market-cap-says-analyst-dan-ives-tech-bull-market-is-still-early" target="_blank" rel="noreferrer noopener">Nvidia, Microsoft On Track To Achieve $4 Trillion Market Cap, Says Analyst Dan Ives: &#8216;Tech Bull Market Is Still Early&#8217;</a></li>
</ul>
Photo via Shutterstock

Tech

BOTZ

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Accenture Deepens Semiconductor Expertise With Dresden-Based SYSTEMA Buy

SHYF

The Shyft Group Merges With Aebi Schmidt To Form Global Specialty Vehicle Leader; New Aebi Schmidt Group Begins NASDAQ Trading July 1

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Tyra Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) with a Buy and maintains $30 price target.

Reiteration

TYRA

HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $30 Price Target

DCGO

DocGo Awarded $3.4M Multi-Year Contract To Provide Ambulance Services For Albany Stratton VA Medical Center Veterans In Upstate New York

LITM

Snow Lake To Invest AUD$1.4M In GTi Energy's AUD$4.5M Equity Financing To Support Advancement Of Lo Herma ISR Amenable Uranium Project

Federal Reserve

Treasury Secretary Bessent On Fox News, Said On Fed, I Will Go Where I Am Needed But We Have A Lot To Do At Treasury

Compass Point analyst Giuliano Bologna initiates coverage on New Fortress Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) with a Buy rating and announces Price Target of $8.5.

Initiation

Compass Point Initiates Coverage On New Fortress Energy with Buy Rating, Announces Price Target of $8.5

Active Ingredient Manufacturing Transfer to the U.S. Complete&nbsp;
PRINCETON, N.J., July 1, 2025 /PRNewswire/ --&nbsp;Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active ingredient under its partnership agreement with Sterling Pharma Solutions (Sterling). The transfer from Europe to the United States (U.S.) included the optimization and implementation of a commercially viable, scalable production process for this important active ingredient, which is used in the topical drug product formulations <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=193312477&amp;u=https%3A%2F%2Fwww.hybryte.com%2F&amp;a=HyBryte%E2%84%A2">HyBryte&#x2122;</a> and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=1271944488&amp;u=https%3A%2F%2Fwww.soligenix.com%2Fpipeline-programs%2Fsgx302-for-mild-to-moderate-psoriasis%2F&amp;a=SGX302">SGX302</a> being developed for the treatment of cutaneous T-cell lymphoma (CTCL) and psoriasis, respectively. Synthetic hypericin is a potent photosensitizer that is topically applied to skin lesions. Soligenix and Sterling have enabled cGMP (current good manufacturing practice) manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.

SNGX

Soligenix Transfers Manufacturing Process For Synthetic Hypericin Active Ingredient Under Partnership Agreement With Sterling Pharma Solutions

Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has exercised its option to license Abeona's patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that result in blindness. This worldwide, non-exclusive license is pursuant to the agreement between Abeona and Beacon, announced in July 2024, to evaluate the therapeutic potential of AAV204.
AAV204, a novel AAV capsid from the AIM&#x2122; capsid library licensed by Abeona from the University of North Carolina at Chapel Hill, has been shown to achieve high macular and optic nerve transduction levels after para-retinal administration and has also been shown to facilitate transduction of both the inner and outer retina after intravitreal administration in mice and non-human primates.
"Beacon's option exercise further validates AAV204's potential to enable targeted delivery of gene therapies in rare and prevalent ophthalmic diseases," said Dr. Madhav Vasanthavada, Chief Commercial Officer and Head of Business Development at Abeona Therapeutics. "Our non-exclusive agreement with Beacon enables us to fully explore the therapeutic value of AAV204 in additional ophthalmic diseases."
The exercise of this license option concludes Beacon's initial evaluation of the AAV204 capsid for development and commercialization of gene therapies and gives Beacon the right to use AAV204 in connection with up to five gene or ophthalmology disease targets. Under the terms of the agreement, Abeona will receive an undisclosed upfront license payment with additional payments upon the achievement of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating AAV204.

Biotech

General

ABEO

Abeona Therapeutics Announces It Has Exercised Its Option To License Abeona's Patented Aav204 Capsid For Use In Potential Gene Therapies

Financing

Snow Lake To Invest AUD$1.4M In GTi Energy's AUD$4.5M Eqiuty Financing To Support Advancement Of Its Lo Herma ISR Amenable Uranium Project

&nbsp;Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active ingredient under its partnership agreement with Sterling Pharma Solutions (Sterling). The transfer from Europe to the United States (U.S.) included the optimization and implementation of a commercially viable, scalable production process for this important active ingredient, which is used in the topical drug product formulations <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=193312477&amp;u=https%3A%2F%2Fwww.hybryte.com%2F&amp;a=HyBryte%E2%84%A2">HyBryte&#x2122;</a> and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=1271944488&amp;u=https%3A%2F%2Fwww.soligenix.com%2Fpipeline-programs%2Fsgx302-for-mild-to-moderate-psoriasis%2F&amp;a=SGX302">SGX302</a> being developed for the treatment of cutaneous T-cell lymphoma (CTCL) and psoriasis, respectively. Synthetic hypericin is a potent photosensitizer that is topically applied to skin lesions. Soligenix and Sterling have enabled cGMP (current good manufacturing practice) manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.

Soligenix Announces That is Successfully Manufactured Synthetic Hypericin At Sterling Pharma Solutions

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Adaptive's clonoSEQ&#xAE; test for measurable residual disease (MRD) assessment in lymphoid malignancies into OncoEMR&#xAE;, Flatiron's cloud-based Electronic Medical Record (EMR) platform.
Integrating clonoSEQ within OncoEMR simplifies and accelerates access to MRD testing to over 4,500 clinicians across the Flatiron network of 1,000 community-based cancer care locations in the U.S. This integration enables providers to order and review clonoSEQ MRD testing results directly within the EMR, leading to more efficient testing workflows and increasing real-time insights into the patient's disease status.
This integration will be effective as of today, July 1, 2025, to all OncoEMR's MPI users. clonoSEQ will continue to be available to providers outside the Flatiron network through a rapidly expanding number of other EMR integrations and via Adaptive's online diagnostic portal.
 &nbsp;

ADPT

Adaptive Biotechnologies Integrates Adaptive's clonosSEQ Test For MRD Assessment In Lymphoid Malignancies Into OncoEMR, Flatiron's Cloud-Based EMR Platform

CGTX

Cognition Therapeutics Study Of Zervimesine (CT1812) For Early Alzheimer's Disease Surpasses 50% Enrollment Target

AMC Enters Transaction Support Agreement With Creditor Groups; Includes ~$223.3M Of New Money Financing, Immediate Conversion Of $143.0M Of 6.00%/8.00% Senior Secured Exchangeable Notes due 2030 And Resolution Of Litigation With Certain Holders Of 7.5% Senior Secured Notes due 2029

Comments

Litman Gregory Funds Trust Polen Capital China Growth ETF

Noticias

Últimas noticias sobre Litman Gregory Funds Trust Polen Capital China Growth ETF (ARCA:PCCE)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL